Key Insights

Highlights

Success Rate

100% trial completion (above average)

Treatment Research

3 treatments under study, led by 11cparaaminobenzoic Acid Petct

Related Conditions

Often studied with 4 related conditions

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 2 trials

Success Rate

100.0%

+13.4% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 2 completed with results

Key Signals

100% success

Data Visualizations

Phase Distribution

1Total
Phase 1 (1)

Trial Status

Completed2

Trial Success Rate

100.0%

Benchmark: 86.6%

Based on 2 completed trials

Clinical Trials (2)

Showing 2 of 2 trials
NCT05611905CompletedPrimary

Biodistribution and Pathophysiology Study of 11C-para-aminobenzoic Acid

NCT00863161Phase 1Completed

Renal Impairment Study

Showing all 2 trials

Research Network

Common Treatments

  • 11cparaaminobenzoic Acid Petct1
  • Lesogaberan1
  • Probenecid1

Active Sponsors

  • Johns Hopkins University1
  • AstraZeneca1
  • National Heart, Lung, and Blood Institute (NHLBI)1

Top Investigators

Related Conditions

  • Reflux1
  • Oncologic Disease1
  • Inflammatory Disease1
  • Bacterial Infections1

Activity Timeline